Type 2 diabetes
Type 2 diabetes: the management of type 2 diabetes (update)
Summary
NICE clinical guideline 87 partially updates NICE clinical guideline 66 and replaces it. Most of the recommendations were developed for NICE clinical guideline 66 by the National Collaborating Centre for Chronic Conditions. Details of the methods and evidence used to develop these recommendations ar ...
There is an incomplete sentence in R32 of the full guideline. The recommendation should read
Consider a sulfonylurea as an option for first-line glucose-lowering therapy if:
- the person is not overweight
- the person does not tolerate metformin (or it is contraindicated) or
- a rapid response to therapy is required because of hyperglycaemic symptoms
Guidance documents
Implementing this guidance
Other information
Expected review date: May 2011
About this guidance
Clinical guidelines CG66
Issued: May 2008
How this guidance was produced